Page last updated: 2024-09-03

b 31 and Local Neoplasm Recurrence

b 31 has been researched along with Local Neoplasm Recurrence in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Badve, S; Bandos, H; Costantino, JP; Demaria, S; Eynden, GGGMVD; Fehrenbacher, L; Floris, G; Gavin, PG; Geyer, CE; Kim, RS; Kos, Z; Lucas, PC; Mamounas, EP; Paik, S; Pogue-Geile, KL; Rastogi, P; Salgado, R; Song, N; Swain, SM; Wickerham, DL; Wolmark, N	1

Other Studies

1 other study(ies) available for b 31 and Local Neoplasm Recurrence

Article	Year
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2019, 08-01, Volume: 111, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrimidines; Receptor, ErbB-2; Receptors, IgG; Stromal Cells; Trastuzumab	2019

Article

Year

Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer.

Journal of the National Cancer Institute, 2019, 08-01, Volume: 111, Issue:8

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Class I Phosphatidylinositol 3-Kinases; Disease-Free Survival; Female; Humans; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrimidines; Receptor, ErbB-2; Receptors, IgG; Stromal Cells; Trastuzumab

2019